Skip to main content
Premium Trial:

Request an Annual Quote

Waters, Protea Ink Co-marketing Pact

NEW YORK (GenomeWeb News) – Waters and Protea Biosciences today announced a co-marketing deal to offer customers Waters' SYNAPT G2 & G2-S HDMS systems with Protea's LAESI DP-1000.

The LAESI DP-1000 system uses Laser Ablation Electrospray Ionization (LAESI) technology to help identify biomolecules such as metabolites, lipids, peptides, and proteins in tissue, blood, and urine, among other samples. The technology requires little or no sample preparation, according to the firms, allowing biomolecules to be "quickly ionized and accurately mapped to specific cellular structures or tissue locations under ambient conditions."

Combined with to high-resolution mass spectrometers, such as the Synapt systems, the LAESI DP-1000 also can quantify biomolecules.

"This collaboration will provide Waters customers an excellent tool for two and three dimensional profiling of tissues and for mapping the spatial distribution of biomolecules in biological samples," Alessandro Baldi, VP and GM at Protea, said in a statement. "In addition, customers are able to directly analyze open well plates for high throughput applications on Waters mass spectrometry instrumentation."

Protea will make the LAESI DP-1000 available to new and existing users of Waters' SYNAPT G2 and SYNAPT G2-S mass spectrometers running under Waters' MassLynx control software.

Financial and further terms of the deal, which was announced at the Pittcon Conference in Orlando, Fla., were not disclosed.